BioAlliance Pharma Launches Loramyc(R) In The UK, Germany And Denmark

BioAlliance Pharma SA (Euronext Paris - BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced the launch of its lead product Loramyc® on the British, German and Danish markets. “This simultaneous product launch in three European countries crowns the efforts of our teams and marks another concrete step in the internationalization of our business.

More: continued here

Filed under: Cancer on July 16th, 2008